- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
OKYO Pharma is planning meetings with the FDA regarding next steps for its clinical trials being conducted in Boston.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
OKYO Pharma is planning meetings with the FDA regarding next steps for its clinical trials being conducted in Boston.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireOKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed gr